Paul O’Connor

1.5k total citations
22 papers, 1.1k citations indexed

About

Paul O’Connor is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Paul O’Connor has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 7 papers in Rheumatology and 6 papers in Oncology. Recurrent topics in Paul O’Connor's work include Multiple Sclerosis Research Studies (16 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Polyomavirus and related diseases (4 papers). Paul O’Connor is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Polyomavirus and related diseases (4 papers). Paul O’Connor collaborates with scholars based in Canada, United States and Switzerland. Paul O’Connor's co-authors include Ludwig Kappos, Massimo Filippi, Douglas Jeffery, Rupert Sandbrink, Stuart D. Cook, Douglas S. Goodin, Hans-Peter Hartung, Barry G.W. Arnason, Gıancarlo Comı and Christoph Pohl and has published in prestigious journals such as NeuroImage, Neurology and The Lancet Neurology.

In The Last Decade

Paul O’Connor

21 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul O’Connor Canada	11	926	329	294	284	220	22	1.1k
Amy Pace United States	8	1.0k 1.1×	555 1.7×	282 1.0×	300 1.1×	252 1.1×	15	1.2k
M. Stojanovic Serbia	8	815 0.9×	361 1.1×	249 0.8×	271 1.0×	241 1.1×	18	1.0k
Hadj Benzerdjeb France	6	713 0.8×	255 0.8×	236 0.8×	233 0.8×	137 0.6×	6	852
Bella Ertik United States	5	756 0.8×	286 0.9×	236 0.8×	272 1.0×	248 1.1×	7	930
C. H. Polman Netherlands	10	788 0.9×	372 1.1×	265 0.9×	252 0.9×	156 0.7×	13	912
Tamara Miller United States	6	799 0.9×	319 1.0×	247 0.8×	288 1.0×	244 1.1×	23	958
Pierangelo Barbero Italy	15	623 0.7×	408 1.2×	289 1.0×	259 0.9×	134 0.6×	34	951
Anthony Hamlett United States	9	953 1.0×	308 0.9×	215 0.7×	411 1.4×	164 0.7×	20	1.2k
Timon Bogumil Germany	12	561 0.6×	216 0.7×	230 0.8×	186 0.7×	181 0.8×	21	1.2k
R. Phillip Kinkel United States	4	1.0k 1.1×	574 1.7×	402 1.4×	241 0.8×	136 0.6×	4	1.1k

Countries citing papers authored by Paul O’Connor

Since Specialization

Citations

This map shows the geographic impact of Paul O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul O’Connor more than expected).

Fields of papers citing papers by Paul O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul O’Connor. The network helps show where Paul O’Connor may publish in the future.

Co-authorship network of co-authors of Paul O’Connor

This figure shows the co-authorship network connecting the top 25 collaborators of Paul O’Connor. A scholar is included among the top collaborators of Paul O’Connor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul O’Connor. Paul O’Connor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Connor, Paul, et al.. (2024). Exploring the Interplay Between Religious Music, Emotions, and Ethics in Cultures Worldwide. Journal of Student Research. 13(2).

Kremenchutzky, Marcelo, Mark Freedman, Amit Bar‐Or, et al.. (2016). Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results (P3.027). Neurology. 86(16_supplement). 1 indexed citations

Hartung, Hans-Peter, Ludwig Kappos, Douglas S. Goodin, et al.. (2015). Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. 262(11). 2466–2471. 3 indexed citations

Montalbán, Xavier, Giancarlo Comi, Jack P. Antel, et al.. (2015). Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Journal of Neurology. 262(12). 2627–2634. 17 indexed citations

Leist, Thomas, Mark Freedman, Ludwig Kappos, et al.. (2015). Pooled Safety Analyses from Teriflunomide Clinical Studies (P7.268). Neurology. 84(14_supplement). 3 indexed citations

Fitzgerald, Kathryn C., Kassandra L. Munger, Karl Köchert, et al.. (2015). Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology. 72(12). 1458–1458. 113 indexed citations

Kremenchutzky, Marcelo, Mark Freedman, Amit Bar‐Or, et al.. (2015). 12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223). Neurology. 84(14_supplement). 2 indexed citations

Hartung, Hans, Lawrence Steinman, Douglas S. Goodin, et al.. (2013). Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. JAMA Neurology. 70(8). 1017–1017. 28 indexed citations

Lampl, Christian, Stefan Nagl, Barry G.W. Arnason, et al.. (2013). Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study. Journal of Neurology. 260(7). 1838–1845. 8 indexed citations

10.

Kremenchutzky, Marcelo, Paul O’Connor, Reinhard Hohlfeld, et al.. (2013). Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders. 3(3). 341–349. 12 indexed citations

11.

O’Connor, Paul, Fred Lublin, Jerry S. Wolinsky, et al.. (2013). Teriflunomide Reduces Relapse-Related Sequelae, Hospitalizations and Corticosteroid Use: A Post-Hoc Analysis of the Phase 3 TOWER Study (P07.109). Neurology. 80(7_supplement). 4 indexed citations

12.

Reder, Anthony T., Joël Oger, Ludwig Kappos, Paul O’Connor, & Mark Rametta. (2013). Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(3). 294–302. 38 indexed citations

13.

Vermersch, Patrick, Anna Członkowska, Christian Confavreux, et al.. (2013). Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 20(6). 705–716. 244 indexed citations

14.

Singer, B., Gıancarlo Comı, Aaron Miller, et al.. (2013). Frequency of Infections during Treatment with Teriflunomide: Pooled Data from Three Placebo-Controlled Teriflunomide Studies (P01.171). Neurology. 80(7_supplement). 5 indexed citations

15.

Devonshire, V., Eva Havrdová, Ernst W. Radue, et al.. (2012). Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. The Lancet Neurology. 11(5). 420–428. 138 indexed citations

16.

Kimball, Samantha, Jodie Burton, Paul O’Connor, & Reinhold Vieth. (2011). Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis. Clinical Biochemistry. 44(10-11). 930–932. 11 indexed citations

17.

Ghaffar, Omar, Nancy J. Lobaugh, Gregory M. Szilagyi, et al.. (2011). Imaging genetics in multiple sclerosis: A volumetric and diffusion tensor MRI study of APOE ε4. NeuroImage. 58(3). 724–731. 3 indexed citations

18.

O’Connor, Paul, Massimo Filippi, Barry G.W. Arnason, et al.. (2009). 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. The Lancet Neurology. 8(10). 889–897. 295 indexed citations

19.

Garnett, William R., et al.. (2005). Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Clinical Therapeutics. 27(7). 1092–1103. 10 indexed citations

20.

Dalton, Catherine M., Katherine Miszkiel, Gareth J. Barker, et al.. (2004). Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. Journal of Neurology. 251(4). 407–413. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact